In 2007, Patrice Cani (FNRS-WELBIO researcher) and his team at the Louvain Drug Research Institute of UCLouvain, in close collaboration with Willem de Vos, professor at UWageningen, discovered the beneficial effects of an intestinal bacteria, Akkermansia muciniphila1, able to moderate the development of obesity and type 2 diabetes, in mice. In 2017, the team discovered (still in the mouse) that the use of a pasteurized form of Akkermansia leads to an even greater protection than the living bacterium regarding various cardiovascular disease risk factors such as insulin resistance, hypercholesterolemia, or the storage of fat in adipose tissue.
Following these discoveries, the UCLouvain team, in collaboration with the Cliniques universitaires Saint-Luc2, developed a clinical study in order to administer the bacteria to humans. For this, it was necessary to develop the capacity to produce the bacterium in large quantity and to make sure that the tests would be without risk for the participants.
The UCLouvain researchers administered Akkermansia to overweight or obese volunteers, all displaying insulin resistance (pre-diabetes type 2) and metabolic syndrome, in other words, having several elevated risk factors for cardiovascular diseases. The volunteers were randomly divided into 3 groups (placebo, live bacteria and pasteurized bacteria) and were asked not to change their dietary habits or their physical activity. Akkermansia was provided as a nutritional supplement.
The primary goal of this UCLouvain study was to demonstrate the feasibility of daily ingesting Akkermansia for 3 months, without risk. Clara Depommier and Amandine Everard, UCLouvain researchers, observed excellent compliance (the supplements were easy to ingest) and tolerance (there were no side effects) in the groups taking live or pasteurized bacteria.
The conclusions are clear: the tests in humans confirm what had already been observed in mice. Ingestion of the (pasteurized) bacterium prevented the deterioration of the health status of the subjects (pre-diabetes, cardiovascular risks). Even better, the researchers observed a decrease in inflammation markers in the liver, a slight decrease in the body weight of the subjects (2.3 kg on average)3 as well as a lowering of cholesterol levels. In contrast, the metabolic parameters (insulin resistance or hypercholesterolemia) in placebo subjects continued to deteriorate over time.
Who does it benefit? According to the WHO, one in three people die every day from cardiovascular disease worldwide. In Western countries, one in two people is overweight and has increased cardiovascular risks. This research of the UCLouvain would limit these risks and therefore potentially have an impact (limit the effects) on half of the population, if properly used.
In conclusion, this pilot study demonstrates the feasibility of administrating (pasteurized) Akkermansia bacteria to humans in the form of a food supplement and reports encouraging results on the effectiveness of the Akkermansia-based dietary supplements to reduce cardio-metabolic risk factors. These results pave the way for a large-scale study, to confirm/elaborate these first results, but also endorse the commercialization of the bacteria as food supplements.
A generic email address has been created for the public who wants more information about Akkermansia bacteria: [email protected].
Learn and see more: A bacteria likely to reduce the cardiovascular risks of 1 in 2 people
The Latest on: Akkermansia
[google_news title=”” keyword=”Akkermansia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Akkermansia
- Doctor shares three foods that could help reduce your risk of type 2 diabeteson May 29, 2023 at 2:20 am
READ MORE: Artificial sweeteners don't help with weight loss in the long term, the WHO warns Another addition Dr Li recommended is concord grapes, which contain the bacteria Akkermansia.
- LivPure Reviews - Is LivPure Official Website Legit Or Fake? What Are Real Customers Saying?on May 18, 2023 at 10:07 pm
Berberine has been shown to alter the composition of gut microbiota by increasing the abundance of beneficial bacteria, such as Akkermansia muciniphila and Bifidobacterium spp., and decreasing the ...
- Prebiotic power: five-year research journey concludes “distinct effect” of cranberry polyphenolson May 16, 2023 at 6:02 am
They were noted to modulate the microbiota and improve gut barrier function through interaction with specific keystone bacteria, such as Akkermansia muciniphila and Bifidobacteria.
- One Day With Jon Bieron January 23, 2022 at 12:04 am
She discusses the importance of the bacterium Akkermansia and why its regulation is key to gut health. Finally, Colleen discusses signs to look for which indicate a recovering microbiome ...
- Is a personalised diet the secret to long-term health?on October 30, 2021 at 5:06 pm
They go by the name of Christensenella and Akkermansia. “It turns out that these are really beneficial microbes,” says Tim. When they put Christensenella into sterile mice, they could “stop ...
- How to be good to your gut (And why it matters)on March 15, 2017 at 1:47 pm
Here are a few things you can do to encourage your bacteria to flourish. Higher numbers of the bacteria Akkermansia are found in people who are naturally slim, leading to suggestions that these ...
- Thanks to a Novel Protein, We Could Bring an End to Obesityon March 3, 2017 at 2:06 am
Since December 2015, Akkermansia-based treatment trials for humans have been ongoing. While the effects are yet to be conclusive, it's clear that the treatment isn't harmful to humans — after ...
via Bing News